Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, has secured $26.5 million in new funding. This investment from a group of investors will bolster the company's financial position as it continues to advance its lead therapeutic candidate. Savara is dedicated to addressing significant unmet medical needs within the rare respiratory disease landscape.
The company's primary focus is MOLBREEVI*, a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) currently in Phase 3 development. MOLBREEVI is being developed for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP), a rare and debilitating lung condition. The investigational therapy is delivered via an eFlow® Nebulizer System (PARI Pharma GmbH), specifically designed for the inhalation of large molecules. Savara's management team brings extensive experience in rare respiratory diseases and pulmonary medicine, guiding the identification of unmet needs and the progression of product candidates through development to potential commercialization.
This capital infusion is expected to primarily support the ongoing clinical development of MOLBREEVI, including its pivotal Phase 3 trial. The funds will also be allocated to general corporate purposes, ensuring the company has the resources necessary to maintain its operational momentum and strategic initiatives. The successful completion of this financing round underscores investor confidence in Savara's pipeline and its approach to developing treatments for rare diseases.
With this significant funding, Savara Inc. is well-positioned to continue its mission of bringing innovative therapies to patients suffering from rare respiratory conditions. The company plans to leverage this investment to further its research and development efforts, aiming to advance MOLBREEVI towards regulatory approval and explore additional opportunities within its therapeutic focus area, ultimately striving to improve patient outcomes.
